Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM1A | O60341 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.60 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl Phenylcarbamate SCHEMBL1222943 | 0.88 | POLB (0.78) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL1870929 | 0.87 | POLB (0.71) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL10598558 | 0.85 | POLB (0.69) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL10595799 | 0.84 | POLB (0.73) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL8867533 | 0.84 | POLB (0.64) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL9080564 | 0.84 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL97634 | 0.84 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL3795024 | 0.84 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL1171853 | 0.84 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL3694153 | 0.84 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20120010161-A1 | NOVEL AZAPEPTIDE OR AZAPEPTIDOMIMETIC COMPOUNDS INHIBITING BCRP AND/OR P-GP | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-01-12 | — | — | US | disclosed |
| EP-1270577-B1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1027328-B1 | SUBSTITUTED ANILIDES | AVENTIS PHARMA LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-6924292-B2 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6479519-B1 | INHIBITORS OF CELL ADHESION; TREATMENT OF ASTHMA OR INFLAMMATORY BOWEL DISEASE | AVENTIS PHARMA LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1027328-A1 | SUBSTITUTED ANILIDES | Aventis Pharma Limited (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999023063-A1 | SUBSTITUTED ANILIDES | AVENTIS PHARMA LIMITED (GB) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010161-A1 | NOVEL AZAPEPTIDE OR AZAPEPTIDOMIMETIC COMPOUNDS INHIBITING BCRP AND/OR P-GP | ABCB1, ABCB11, ABCC1 | POLB 3349/4885TP53 234/4885MAPT 4315/4885 |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | PDE3B, PDE5A, PDE3A | POLB 1153/4885TP53 3833/4885MAPT 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.